NCT03748784 - ADVM-022 Intravitreal Gene Therapy for Wet AMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions

Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL

ADVM-022

ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept

Trial Locations (11)

19107

Adverum Clinical Site, Philadelphia

29169

Adverum Clinical Site, West Columbia

33064

Adverum Clinical Site, Deerfield Beach

37203

Adverum Clinical Site, Nashville

77030

Adverum Clinical Site, Houston

77384

Adverum Clinical Site, The Woodlands

79606

Adverum Clinical Site, Abilene

80401

Adverum Clinical Site, Golden

89502

Adverum Clinical Site, Reno

90211

Adverum Clinical Site, Beverly Hills

93309

Adverum Clinical Site, Bakersfield